Skip to content

Pairing Subjective Patient Rating and DBS Programming

Pairing Subjective Patient Rating and Local Field Potentials for DBS Programming

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07336199
Acronym
PERCEPT-DBS
Enrollment
25
Registered
2026-01-13
Start date
2024-12-02
Completion date
2026-10-01
Last updated
2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease (PD)

Brief summary

This multicenter, prospective and retrospective diagnostic study investigates personalized programming strategies for deep brain stimulation (DBS) in patients with Parkinson's disease. DBS of the subthalamic nucleus (STN) is an established therapy for advanced Parkinson's disease; however, optimization of stimulation parameters remains time-consuming and resource-intensive due to the growing complexity of electrode designs and programming options. The PERCEPT-DBS study aims to improve DBS programming by combining subjective patient-reported outcomes with objective electrophysiological biomarkers. Specifically, the study examines the relationship between patients' subjective assessment of stimulation efficacy, measured using a visual analogue scale (VAS), and local field potentials (LFPs), with a focus on beta-band activity recorded from implanted DBS electrodes. These data are integrated with structural and functional neuroimaging to identify individualized stimulation sweet spots within the STN. A total of 24 patients with idiopathic Parkinson's disease treated with bilateral STN-DBS will be recruited across several German DBS centers. Participants undergo standardized clinical assessments, VAS-based blinded monopolar reviews, and LFP recordings using sensing-enabled implantable pulse generators. In addition, imaging-based analyses are performed to relate electrophysiological and subjective measures to anatomical and connectomic features. The primary objective is to determine whether electrophysiological markers correlate with subjective patient ratings and whether their overlap defines personalized optimal stimulation targets. By integrating patient perception with neurophysiological and imaging data, this study seeks to advance individualized DBS programming strategies and contribute to the development of more efficient, patient-centered, and potentially adaptive DBS therapies.

Interventions

OTHERNo intervention (observational study)

No intervention (observational study)

Sponsors

Medtronic
CollaboratorINDUSTRY
Ludwig-Maximilians - University of Munich
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
35 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Age between 35 and 80 years Clinically confirmed idiopathic Parkinson's disease according to Movement Disorder Society (MDS) criteria Status post bilateral deep brain stimulation of the subthalamic nucleus (STN-DBS) Implanted DBS system suitable for electrophysiological recordings (prospective cohort: sensing-enabled IPG) Ability to understand study procedures and communicate reliably with the investigator Written informed consent provided

Exclusion criteria

Any condition impairing the ability to provide informed consent or comply with study procedures Presence of

Design outcomes

Primary

MeasureTime frameDescription
Correlation between beta-band local field potentials and patient-reported DBS efficacy30 to 45 days after DBS electrode implantation (first study visit)The primary outcome is the relationship between electrophysiological activity recorded from the subthalamic nucleus and subjective patient assessment of deep brain stimulation (DBS) efficacy. Beta-band (13-30 Hz) local field potential (LFP) amplitude recorded from implanted DBS electrodes is correlated with patient-reported ratings of overall stimulation quality measured using a visual analogue scale (VAS) during blinded monopolar programming. Outcome analyses assess whether electrophysiological markers correspond to higher subjective DBS benefit and whether overlapping signals define individualized stimulation sweet spots.

Countries

Germany

Contacts

Primary ContactThomas Köglsperger, PD Dr. med., MHBA
thomas.koeglsperger@med.uni-muenchen.de+4989440073901

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026